Wellington Management Group LLP Purchases Shares of 2,919,110 Kailera Therapeutics, Inc. $KLRA

Wellington Management Group LLP acquired a new position in shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 2,919,110 shares of the company’s stock, valued at approximately $64,308,000.

Analyst Ratings Changes

KLRA has been the subject of several analyst reports. William Blair began coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They issued an “outperform” rating for the company. Jefferies Financial Group began coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $48.00 price target for the company. JPMorgan Chase & Co. started coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They issued an “overweight” rating and a $30.00 price objective for the company. TD Cowen started coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They set a “buy” rating and a $57.00 price objective on the stock. Finally, Leerink Partners started coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They issued an “outperform” rating and a $36.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $42.75.

Kailera Therapeutics Stock Performance

KLRA opened at $15.85 on Thursday. Kailera Therapeutics, Inc. has a 12-month low of $15.15 and a 12-month high of $28.23. The company has a 50 day simple moving average of $18.73. The firm has a market capitalization of $2.05 billion and a PE ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA) last posted its earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.35). As a group, analysts forecast that Kailera Therapeutics, Inc. will post -3.89 earnings per share for the current year.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.